(Q50566963)

15 March 2018

title

N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. (English)

1 reference

15 March 2018

obsessive-compulsive disorder

1 reference

1 reference

3

1 reference

15 March 2018

Michael Berk

object named as

Michael Berk

9

0 references

Olivia M. Dean

4

object named as

Olivia M Dean

1 reference

15 March 2018

author name string

Jerome Sarris

1

1 reference

15 March 2018

Georgina Oliver

2

1 reference

15 March 2018

Nathan Dowling

5

1 reference

15 March 2018

Deidre J Smith

6

1 reference

15 March 2018

Jenifer Murphy

7

1 reference

15 March 2018

Ranjit Menon

8

1 reference

15 March 2018

Scott Blair-West

10

1 reference

15 March 2018

Chee H Ng

11

1 reference

15 March 2018

publication date

15 September 2015

1 reference

15 March 2018

published in

CNS Drugs

1 reference

15 March 2018

volume

29

1 reference

15 March 2018

page(s)

801-809

1 reference

15 March 2018

issue

9

1 reference

15 March 2018

https://scigraph.springernature.com/pub.10.1007/s40263-015-0272-9

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Brain corticostriatal systems and the major clinical symptom dimensions of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Meta-analysis of brain volume changes in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Anatomical alterations and symptom-related functional activity in obsessive-compulsive disorder are correlated in the lateral orbitofrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Repeated cortico-striatal stimulation generates persistent OCD-like behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Obsessive compulsive disorder and the glutamatergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Glutamatergic dysfunction in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Distribution of the cystine/glutamate antiporter system xc- in the brain, kidney, and duodenum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Relationship of possible stress-related biochemical markers to oxidative/antioxidative status in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

The promise of N-acetylcysteine in neuropsychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0272-9

10.1007/S40263-015-0272-9

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

PubMed ID

26374743

1 reference

15 March 2018